Stock MRNS MARINUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.405 USD -1.06% Intraday chart for Marinus Pharmaceuticals, Inc. +1.81% -87.07%
Apr. 17 Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating MT
Apr. 16 Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2 MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
BU
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus Post Grant Review
AQ
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
BU
Marinus Pharmaceuticals: Q4 Earnings Snapshot
AQ
Marinus Pharmaceuticals : Corporate Overview Slide Deck
PU
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
BU
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
BU
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY Net Product Revenue and Provides Business Update
AQ
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update
BU
Marinus Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
Marinus Pharmaceuticals : Corporate Overview Slide Deck
PU
Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study
BU
Marinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference
BU
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY Oral Suspension CV
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRNS Stock
  4. News Marinus Pharmaceuticals, Inc.
  5. Press Releases